Expansion Opportunity Gilead’s substantial investment in a new research center in Foster City signals ongoing capacity growth and a readiness to deploy advanced biopharma capabilities. Explore partnerships or contract research, process optimization, and CRO/CMC services to support the scale-up and innovation initiatives at this facility.

HIV Portfolio Growth Recent launches and ongoing HIV program development such as Bixlenvo and islatravir/lenacapavir indicate a strong need for integrated supply chain, pharmacovigilance, and commercialization support. Propose end-to-end services from clinical analytics to post-market surveillance and market access strategy.

Competitive Intelligence Gilead faces competitive pressure in cell-therapy and TY/oncology segments, with Trodelvy performance and headcount reductions in certain areas. Offer competitive benchmarking, market analytics, and strategic partnerships to bolster Gilead’s differentiation in oncology and cell therapy.

AI and Data Enablement The collaboration with Deepcell on AI-driven CHO morphology suggests openness to AI/ML-enabled bioprocessing and data science solutions. Present opportunities for AI-enabled drug discovery, predictive manufacturing analytics, and digital twin capabilities to accelerate development timelines.

Financial Levers With robust revenue and sizable funding, Gilead may pursue efficiency, integration, or portfolio optimization initiatives post headcount adjustments. Propose cost optimization, scalable cloud-based analytics, and project-based partnerships to support leaner operations without compromising R&D momentum.